Abstract:Abstract Abstract 2689 Poster Board II-665 Introduction: Extranodal NK/T-cell lymphoma (ENKL) is a distinct clinicopathological entity of non-Hodgkin's lymphoma, which is characterized by a highly aggressive clinical process and poor prognosis. There are no standard treatment strategies available now. The present study aimed to evaluate the treatment outcome and toxicity of EPOCH regimen for ENKL. Methods: From June 2003 to June 2008, 34 patients including 30 nasal ENKL (88.2%) and 4 extranasal ENKL (11.8%) received doxorubicin, vincristine, etoposide over 96 hours infusion with bolus cyclophosphamide and oral predinisone (EPOCH) combination as first-line treatment. By the Ann Arbor lymphoma Staging Classification, 29 patients (85.3%) had stage ±E-IIE disease and 5 patients (14.7%) had stage IIIE-‡WE disease. Median cycles of EPOCH regimen administered were 2.5 (range from 1 to 6 cycles). Additional involved field radiation therapy (IFRT) was administered to patients with localized regional disease after chemotherapy. Results: Among 34 patients, 33 were eligible for objective response evaluation. The response rate (RR) for the whole group was 60.6% (20/33) with complete remission (CR) rate of 45.5% (15/33). The RR of patients with nasal ENKL was 66.7% (20/30), the CR rate was 50% (15/30). Of the 4 patients with extranasal ENKL, only one achieved stable disease (SD), the other three had progressive disease (PD) during chemotherapy. After a median follow-up of 22 (2–68) months, the estimated overall 3-year overall survival rate (OS) was 52.2%. For patients with nasal ENKL, the estimated median survival time was not reached, the 3-year OS was 59.4%. For patients with extranasal ENKL, the estimated median survival time was only 7 months. For stage ±E-IIE patients with nasal ENKL who received initial EPOCH chemotherapy followed IFRT, the CR rate was 75.0%, and the 3-year survival rate was 75.0%. 102 cycles of chemotherapy were administered to 34 patients. Major adverse effect was myelosuppression. The incidence of grade III-‡W neutropenia was 30.9% and 60 cycles needed G-CSF support. Other toxicities were mild, no treatment-related mortality occurred. Conclusion: EPOCH regiment was effective on ENKL with acceptable toxlicity. EPOCH followed by IFRT yielded promising outcome for patients with localized nasal ENKL. However, patients with extranasal ENKL responded poorly, and more efficacious treatment strategies are urgently needed. Disclosures: No relevant conflicts of interest to declare.

Promising clinical outcomes of sequential and "Sandwich" chemotherapy and extended involved-field intensity-modulated radiotherapy in patients with stage I E /II E extranodal natural killer/T-cell lymphoma.

Analysis of the treatment and prognosis of 266 cases of extranodal natural killer/T-cell lymphoma, nasal type in a single medical center

A Multicenter Retrospective Comparison of Sequential Versus Sandwich Chemoradiotherapy for Stage IE-IIE Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.

Phase 2 trial of "sandwich" L -asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma

Clinical Characteristics and Treatment of 69 Patients with Extranodal Natural Killer T-cell Lymphoma

"Sandwich" Chemotherapy (Ct) With Radiotherapy (Rt) Improves Outcomes In Patients With Stage I-E/Iie Extranodal Natural Killer (Nk)/T-Cell Lymphomas

The Promising Outcome with Simultaneous Integrated Boost Intensity Modulated Radiotherapy in Confined Nasal Extranodal NK/T-cell Lymphoma.

A Phase Ii Prospective Study of the "sandwich" Protocol, L-Asparaginase, Cisplatin, Dexamethasone and Etoposide Chemotherapy Combined with Concurrent Radiation and Cisplatin, in Newly Diagnosed, I/Ii Stage, Nasal Type, Extranodal Natural Killer/T-Cell Lymphoma

Radiotherapy followed by DICEP regimen in treatment of newly diagnosed, stage IE/IIE, extranodal NK/T-cell lymphoma patients.

Retrospective Analysis of Outcome Differences in Preoperative Concurrent Chemoradiation with or Without Elective Nodal Irradiation for Esophageal Squamous Cell Carcinoma

Extended Course and Increased Dose of Initial Chemotherapy for Extranodal Nasal Type Natural Killer/T (NK/T)-Cell Lymphoma in Patients <60 Years Old: A Single-Center Retrospective Cohort Study.

Extended Course and Increased Dose of Initial Chemotherapy for Extranodal Nasal Type Natural Killer/T (Nk/t)-Cell Lymphoma in Patients <60 Years Old: A Single-Center Retrospective Cohort Study

Long-Term Efficacy of Sequential Dice Chemotherapy with Regional Field Radiation Therapy for Stages I-Ii Natural Killer/T-Cell Lymphoma, Nasal Type: Analysis of 118 Cases

[Outcome of Radiotherapy for Low-Risk Early-Stage Patients with Extranodal NK/T-cell Lymphoma, Nasal-Type].

Longterm Outcome of Induction Chemotherapy of P-Gemox Regimen Followed by Extensive Involved-Field Radiotherapy(Eifrt) for Newly Diagnosed Stage I/Ii Extranodal Natural Killer/T-Cell Lymphoma-A Single Center Experience

Long-Term Outcomes of Patients with Newly Diagnosed Nk/T-Cell Lymphoma Treated by Epoch Regimen

Chemotherapy combined with high-dose extended-field radiotherapy for stage I extranodal nasal-type natural killer/T-cell lymphoma

Sequential P‐GEMOX and radiotherapy for early‐stage extranodal natural killer/ T‐ cell lymphoma: A multicenter study

Preliminary Outcome of Concurrent Chemoradiation Therapy in Patients with Early Stage Extranodal Nasal Type NK/T-cell Lymphoma

Treatment outcomes and prognostic analysis of elderly patients with extranodal natural killer/T-cell lymphoma, nasal type: a retrospective analysis

Clinicopathological characteristics and treatment outcomes of cutaneous extranodal natural killer/T-cell lymphoma: a retrospective study in China